# SBIR Phase II: Protein A Membrane Columns for Rapid Protein Purification

> **NIH NIH R44** · PURILOGICS, LLC · 2020 · $289,381

## Abstract

Project Summary
This SBIR Urgent Competitive Revision will develop the first affinity membrane to purify therapeutic mRNA with
high selectivity and throughput. mRNA-based pharmaceuticals have potential to address a wide variety of
pathologies. mRNA-based vaccines can increase safety and dramatically shorten development timelines in
pandemic scenarios. A number of mRNA-based COVID-19 vaccines are under development, and one such
vaccine has completed its Phase-I clinical trial and showed great promise as a response to the COVID-19
pandemic. However, a company pioneering mRNA medicines has revealed that the lack of high throughput
downstream purification processes is a major hurdle that must be addressed in the upscaling of industrial
mRNA production to yield the necessary quantity and quality. Considering the profound impact that COVID-19
will have on the global population of nearly seven billion people, the time to develop a high productivity mRNA
purification technology, like the one proposed, is now. By addressing this challenge, the proposed technology
will have a significant impact on mRNA production and, by association, improve patient accessibility to the
vaccine. Therapeutic mRNA usually possesses a polyadenylic acid (poly-A) tail. Oligo-deoxythymidine (oligo-
dT) has been recognized as effective affinity ligand to isolate polyadenylated mRNA from feed streams via
hybridization between adenine in the poly-A tail and deoxythymidine in oligo-dT. The goal of this Competitive
Revision project is to demonstrate the feasibility of developing dT-based affinity membrane products with high
binding capacity for the rapid and selective purification of polyadenylated mRNA. Preliminary data are highly
encouraging. The products derived from this innovation will be first-in-market, disposable membrane
chromatography columns that can improve the mRNA purification productivity up to one hundred times with
high purity and yield compared to conventional resin columns. The Specific Aims of the study are to (1)
synthesize and characterize mRNA affinity membranes and (2) test prototype affinity membrane columns for
capture step purification of polyadenylated mRNA. In Specific Aim 1, Purilogics will evaluate the roles played
by ligand structure and density, synthesis conditions, and bind-and-elute conditions on capacity and recovery
using a commercially available purified mRNA. In Specific Aim 2, Purilogics will collaborate with a partner
contract manufacturing organization to quantify membrane column performance for capture step purification of
polyadenylated mRNA prepared with in vitro transcription (IVT) processes. The prototypes also will be
benchmarked against existing products. Multiple iterations of synthesis and performance characterization will
improve membrane performance. Immediate market entry for the new column products will be sales to
purification scientists and engineers in biopharmaceutical companies.

## Key facts

- **NIH application ID:** 10174506
- **Project number:** 3R44GM125429-03S1
- **Recipient organization:** PURILOGICS, LLC
- **Principal Investigator:** Jinxiang Zhou
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $289,381
- **Award type:** 3
- **Project period:** 2017-08-01 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10174506

## Citation

> US National Institutes of Health, RePORTER application 10174506, SBIR Phase II: Protein A Membrane Columns for Rapid Protein Purification (3R44GM125429-03S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10174506. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*